UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome

Author
David H Weinberg, MD
Section Editors
Lisa M DeAngelis, MD, FAAN, FANA
Jeremy M Shefner, MD, PhD
Deputy Editor
John F Dashe, MD, PhD

INTRODUCTION

Lambert-Eaton myasthenic syndrome (LEMS) is an uncommon disorder of neuromuscular junction transmission with the primary clinical manifestation of muscle weakness. Knowledge of subtle clinical features and laboratory abnormalities that accompany LEMS permits the early identification of the disorder. Early recognition is particularly important because of its strong association with small cell lung cancer (SCLC). Although LEMS can occur at any point in the course of SCLC, it may serve as a marker for early disease.

This topic will review the pathophysiology, clinical features, and diagnosis of LEMS. Treatment of LEMS is discussed separately. (See "Treatment of Lambert-Eaton myasthenic syndrome".)

PATHOPHYSIOLOGY

Lambert and Elmqvist, through a series of elegant intracellular muscle recordings, found that patients with what is now called Lambert-Eaton myasthenic syndrome (LEMS) had the following unique features [1,2]:

Normal miniature endplate potential amplitude, demonstrating normal postsynaptic sensitivity to acetylcholine (ACh)

Markedly reduced evoked endplate potential amplitude, suggesting a significant reduction in ACh release

             

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Wed Mar 02 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Lambert EH, Elmqvist D. Quantal components of end-plate potentials in the myasthenic syndrome. Ann N Y Acad Sci 1971; 183:183.
  2. Elmqvist D, Lambert EH. Detailed analysis of neuromuscular transmission in a patient with the myasthenic syndrome sometimes associated with bronchogenic carcinoma. Mayo Clin Proc 1968; 43:689.
  3. Molenaar PC, Newsom-Davis J, Polak RL, Vincent A. Eaton-Lambert syndrome: acetylcholine and choline acetyltransferase in skeletal muscle. Neurology 1982; 32:1061.
  4. Motomura M, Johnston I, Lang B, et al. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1995; 58:85.
  5. Lang B, Pinto A, Giovannini F, et al. Pathogenic autoantibodies in the lambert-eaton myasthenic syndrome. Ann N Y Acad Sci 2003; 998:187.
  6. Pinto A, Gillard S, Moss F, et al. Human autoantibodies specific for the alpha1A calcium channel subunit reduce both P-type and Q-type calcium currents in cerebellar neurons. Proc Natl Acad Sci U S A 1998; 95:8328.
  7. Benatar M, Blaes F, Johnston I, et al. Presynaptic neuronal antigens expressed by a small cell lung carcinoma cell line. J Neuroimmunol 2001; 113:153.
  8. Lang B, Vincent A, Murray NM, Newsom-Davis J. Lambert-Eaton myasthenic syndrome: immunoglobulin G inhibition of Ca2+ flux in tumor cells correlates with disease severity. Ann Neurol 1989; 25:265.
  9. Lang B, Newsom-Davis J, Wray D, et al. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet 1981; 2:224.
  10. Kim YI. Passive transfer of the Lambert-Eaton myasthenic syndrome: neuromuscular transmission in mice injected with plasma. Muscle Nerve 1985; 8:162.
  11. Kim YI. Passively transferred Lambert-Eaton syndrome in mice receiving purified IgG. Muscle Nerve 1986; 9:523.
  12. Kim YI, Sanders DB, Johns TR, et al. Lambert-Eaton myasthenic syndrome: the lack of short-term in vitro effects of serum factors on neuromuscular transmission. J Neurol Sci 1988; 87:1.
  13. Dau PC, Denys EH. Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert syndrome. Ann Neurol 1982; 11:570.
  14. Newsom-Davis J, Murray NM. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 1984; 34:480.
  15. Motomura M, Hamasaki S, Nakane S, et al. Apheresis treatment in Lambert-Eaton myasthenic syndrome. Ther Apher 2000; 4:287.
  16. Wirtz PW, Nijnuis MG, Sotodeh M, et al. The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland. J Neurol 2003; 250:698.
  17. Hajjar M, Markowitz J, Darras BT, et al. Lambert-Eaton syndrome, an unrecognized treatable pediatric neuromuscular disorder: three patients and literature review. Pediatr Neurol 2014; 50:11.
  18. O'Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988; 111 ( Pt 3):577.
  19. Elrington GM, Murray NM, Spiro SG, Newsom-Davis J. Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients. J Neurol Neurosurg Psychiatry 1991; 54:764.
  20. Payne M, Bradbury P, Lang B, et al. Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer. J Thorac Oncol 2010; 5:34.
  21. Wirtz PW, Lang B, Graus F, et al. P/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer. J Neuroimmunol 2005; 164:161.
  22. Titulaer MJ, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms. Ann N Y Acad Sci 2008; 1132:129.
  23. Argov Z, Shapira Y, Averbuch-Heller L, Wirguin I. Lambert-Eaton myasthenic syndrome (LEMS) in association with lymphoproliferative disorders. Muscle Nerve 1995; 18:715.
  24. Gutmann L, Phillips LH 2nd, Gutmann L. Trends in the association of Lambert-Eaton myasthenic syndrome with carcinoma. Neurology 1992; 42:848.
  25. Siau RT, Morris A, Karoo RO. Surgery results in complete cure of Lambert-Eaton myasthenic syndrome in a patient with metastatic Merkel cell carcinoma. J Plast Reconstr Aesthet Surg 2014; 67:e162.
  26. Lemal R, Chaleteix C, Minard P, et al. Large granular lymphocytic leukemia associated with Lambert-Eaton Myasthenic Syndrome: A case report. Leuk Res Rep 2013; 2:32.
  27. Nalbantoglu M, Kose L, Uzun N, et al. Lambert-Eaton myasthenic syndrome associated with thymic neuroendocrine carcinoma. Muscle Nerve 2015; 51:936.
  28. Lauritzen M, Smith T, Fischer-Hansen B, et al. Eaton-Lambert syndrome and malignant thymoma. Neurology 1980; 30:634.
  29. Wirtz PW, Bradshaw J, Wintzen AR, Verschuuren JJ. Associated autoimmune diseases in patients with the Lambert-Eaton myasthenic syndrome and their families. J Neurol 2004; 251:1255.
  30. Lennon VA, Lambert EH, Whittingham S, Fairbanks V. Autoimmunity in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1982; 5:S21.
  31. Wirtz PW, Wintzen AR, Verschuuren JJ. Lambert-Eaton myasthenic syndrome has a more progressive course in patients with lung cancer. Muscle Nerve 2005; 32:226.
  32. EATON LM, LAMBERT EH. Electromyography and electric stimulation of nerves in diseases of motor unit; observations on myasthenic syndrome associated with malignant tumors. J Am Med Assoc 1957; 163:1117.
  33. Titulaer MJ, Wirtz PW, Kuks JB, et al. The Lambert-Eaton myasthenic syndrome 1988-2008: a clinical picture in 97 patients. J Neuroimmunol 2008; 201-202:153.
  34. O'Suilleabhain P, Low PA, Lennon VA. Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates. Neurology 1998; 50:88.
  35. Wirtz PW, Sotodeh M, Nijnuis M, et al. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2002; 73:766.
  36. Burns TM, Russell JA, LaChance DH, Jones HR. Oculobulbar involvement is typical with Lambert-Eaton myasthenic syndrome. Ann Neurol 2003; 53:270.
  37. Rudnicki SA. Lambert-Eaton myasthenic syndrome with pure ocular weakness. Neurology 2007; 68:1863.
  38. Laroche CM, Mier AK, Spiro SG, et al. Respiratory muscle weakness in the Lambert-Eaton myasthenic syndrome. Thorax 1989; 44:913.
  39. Barr CW, Claussen G, Thomas D, et al. Primary respiratory failure as the presenting symptom in Lambert-Eaton myasthenic syndrome. Muscle Nerve 1993; 16:712.
  40. Nicolle MW, Stewart DJ, Remtulla H, et al. Lambert-Eaton myasthenic syndrome presenting with severe respiratory failure. Muscle Nerve 1996; 19:1328.
  41. Beydoun SR. Delayed diagnosis of Lambert-Eaton myasthenic syndrome in a patient presenting with recurrent refractory respiratory failure. Muscle Nerve 1994; 17:689.
  42. Breen LA, Gutmann L, Brick JF, Riggs JR. Paradoxical lid elevation with sustained upgaze: a sign of Lambert-Eaton syndrome. Muscle Nerve 1991; 14:863.
  43. Clark CV, Newsom-Davis J, Sanders MD. Ocular autonomic nerve function in Lambert-Eaton myasthenic syndrome. Eye (Lond) 1990; 4 ( Pt 3):473.
  44. Newsom-Davis J, Leys K, Vincent A, et al. Immunological evidence for the co-existence of the Lambert-Eaton myasthenic syndrome and myasthenia gravis in two patients. J Neurol Neurosurg Psychiatry 1991; 54:452.
  45. Oh SJ. Myasthenia gravis Lambert-Eaton overlap syndrome. Muscle Nerve 2016; 53:20.
  46. Mason WP, Graus F, Lang B, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 1997; 120 ( Pt 8):1279.
  47. Nakao YK, Motomura M, Fukudome T, et al. Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology 2002; 59:1773.
  48. Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 2011; 10:1098.
  49. Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995; 332:1467.
  50. Pellkofer HL, Armbruster L, Krumbholz M, et al. Lambert-eaton myasthenic syndrome differential reactivity of tumor versus non-tumor patients to subunits of the voltage-gated calcium channel. J Neuroimmunol 2008; 204:136.
  51. Oh SJ, Kim DE, Kuruoglu R, et al. Electrophysiological and clinical correlations in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1996; 19:903.
  52. AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: summary statement. Muscle Nerve 2001; 24:1236.
  53. AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome. Muscle Nerve 2001; 24:1239.
  54. Tim RW, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment. Neurology 2000; 54:2176.
  55. Oh SJ. Diverse electrophysiological spectrum of the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1989; 12:464.
  56. Oh SJ, Hatanaka Y, Claussen GC, Sher E. Electrophysiological differences in seropositive and seronegative Lambert-Eaton myasthenic syndrome. Muscle Nerve 2007; 35:178.
  57. Bady B, Truffert A, Brechard M, et al. [Electrophysiologic data on myasthenic syndromes of the Lambert-Eaton type. A series of 23 cases]. Neurophysiol Clin 1992; 22:27.
  58. Oh SJ, Kurokawa K, Claussen GC, Ryan HF Jr. Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve 2005; 32:515.
  59. Tim RW, Sanders DB. Repetitive nerve stimulation studies in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1994; 17:995.
  60. Hatanaka Y, Oh SJ. Ten-second exercise is superior to 30-second exercise for post-exercise facilitation in diagnosing Lambert-Eaton myasthenic syndrome. Muscle Nerve 2008; 37:572.
  61. Oh SJ, Hatanaka Y, Ito E, Nagai T. Post-exercise exhaustion in Lambert-Eaton myasthenic syndrome. Clin Neurophysiol 2014; 125:411.
  62. Trontelj JV, Stålberg E. Single motor end-plates in myasthenia gravis and LEMS at different firing rates. Muscle Nerve 1991; 14:226.
  63. Chaudhry V, Watson DF, Bird SJ, Cornblath DR. Stimulated single-fiber electromyography in Lambert-Eaton myasthenic syndrome. Muscle Nerve 1991; 14:1227.
  64. Oh SJ, Ohira M. Single-fiber EMG and clinical correlation in Lambert-Eaton myasthenic syndrome. Muscle Nerve 2013; 47:664.
  65. Crone C, Christiansen I, Vissing J. Myopathic EMG findings and type II muscle fiber atrophy in patients with Lambert-Eaton myasthenic syndrome. Clin Neurophysiol 2013; 124:1889.
  66. Kim YI. Lambert-Eaton myasthenic syndrome: evidence for calcium channel blockade. Ann N Y Acad Sci 1987; 505:377.